Zwei Meldungen lassen aufhorchen, is ja schön ausgebombt das Teil.
Gruss E.
XOMA Licenses BPI to Zephyr Sciences, Inc.
BERKELEY, Calif., Nov 10, 2004 (BUSINESS WIRE) -- XOMA Ltd. (NASDAQ: XOMA)
announced today that it has entered into an exclusive worldwide licensing
agreement with Zephyr Sciences, Inc. (Zephyr) for the research, development and
commercialization of products related to its
bactericidal/permeability-increasing protein (BPI), including its NEUPREX(R)
product. The agreement does not cover BPI-derived peptide products. Under the
terms of the agreement, XOMA will be entitled to receive license fees totaling
up to $11 million and milestone payments totaling up to $62 million, as well as
royalties on sales of future products developed and approved under the
agreement. The agreement also includes due diligence provisions related to the
development of BPI in multiple indications, and Zephyr will fund all future
research and development activities. Other financial terms of the license were
not disclosed.
Nov 10, 2004 (M2 PRESSWIRE via COMTEX) -- The Bellwether Report has issued an
aggressive investor alert for shareholders in Xoma Ltd (Nasdaq: XOMA), a
biopharmaceutical company that develops and manufactures products to treat
immunologic and inflammatory disorders, cancer and infectious diseases.
BWR has identified this companies and our analysts will be keeping a close watch
on it over the course of trading as the company came out with a significant
corporate developments yesterday after the Bell.
The company recorded a net loss of $20.1 million or $0.24 per share, compared
with $9.9 million or $0.13 per share for the third quarter of 2003. As of
September 30, 2004, XOMA held $36.4 million in cash, cash equivalents, and
short-term investments, compared with $85.2 million at December 31, 2003.
Zurück
"
